INmune Bio publishes phase 2 alzheimer's trial results in peer journal

May 15, 2026 8:00 AM

INmune Bio Inc. (NASDAQ: INMB) announced that results from its Phase 2 MINDFuL trial evaluating XPro1595 in Alzheimer's disease patients ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found